Satoh K, Nunoki K, Goto T, Hosono M, Hashimoto H, Sato Y, Taira N
Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan.
Jpn J Pharmacol. 1988 Jun;47(2):189-95. doi: 10.1254/jjp.47.189.
The efficacy of MCI-154, a new pyridazinone cardiotonic agent, in improving heart failure was assessed in dog heart-lung preparations in which cardiac function had been severely depressed by pentobarbital. MCI-154 in doses of 10-100 micrograms improved the cardiac function curve and restored it to the control level at 100 micrograms. At this dose, MCI-154 neither produced an increase in heart rate beyond the control value nor induced arrhythmias. The effects of MCI-154 were not affected by atenolol, a cardioselective beta 1-blocker. These results indicate that MCI-154 would be of potential use in the treatment of heart failure.
新型哒嗪酮强心剂MCI - 154改善心力衰竭的疗效在犬心肺制备模型中进行了评估，该模型中心脏功能已被戊巴比妥严重抑制。剂量为10 - 100微克的MCI - 154改善了心功能曲线，并在剂量为100微克时将其恢复到对照水平。在此剂量下，MCI - 154既不会使心率超过对照值，也不会诱发心律失常。MCI - 154的作用不受心脏选择性β1阻滞剂阿替洛尔的影响。这些结果表明MCI - 154在心力衰竭治疗中具有潜在用途。
